Ovarian clear cell carcinoma associated with endometriosis: a case report and literature review

Purpose: The purpose of this report was to confirm that endometriosis, although a benign gynecological disease, in some patients, can give rise to ovarian cancers. Case Report: The authors report a case of clear cell carcinoma in a patient suffering of endometriosis. The patient, a 38-year old nullipara, had a history of bilateral ovarian cysts diagnosed on routine check-up by ultrasound scan four years ago. After admission to hospital, due to cramping lower abdominal pain, MRI showed tumorous mass, with solid and cystic components, located between abdominal wall, lateral pelvic walls, and lumbosacral part of spine belonging to ovaries. The patient underwent appropriate extensive surgery. Histopathological investigation revealed ovarian clear cell adenocarcinoma Stage IIIa, along with endometriotic cyst found on the contralateral side. Conclusion: This report confirms the strong link between endometriosis and ovarian cancer and sends an appeal for urgent and precise definition of parameters relevant for determination of patients’ groups with the risk for malignancy.

Clear cell carcinoma; Endometriosis; Ovarian tumor

[1] Mandai M., Matsumura N., Baba T., Yamaguchi K., Hamanishi J., Konishi I.: “Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype”. Cancer Letters, 2011, 310, 129.

[2] Anglesio M.S., Yong P.J.: “Endometriosis-associated Ovarian Cancers”. Clin. Obstet. Gynecol., 2017, 60, 711.

[3] Szubert M., Suzin J., Obirek K., Sochacka A., Loszakiewicz M.: “Clear cell ovarian cancer and endometriosis: is there a relationship?” Prz. Menopauzalny., 2016, 15, 85.

[4] Ovarian Cancer Association Consortium.: “Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies”. Lancet Oncol., 2012, 13, 385

[5] Terada T.: “Clear cell adenocarcinoma of the ovary arising in atypical endometriosis: a report of eight cases”. Arch. Gynecol. Obstet., 2012, 285, 229.

[6] Del Carmen M.G., Birrer M., Schorge J.O.: “Clear cell carcinoma of the ovary: A review of the literature“. Gynecol. Oncol., 2012, 126, 481

[7] Kondi-Pafiti A., Papakonstantinou E., Iavazzo C., Grigoriadis C., Salakos N., Gregoriou O.: “Clinicopathological characteristics of ovarian carcinomas associated with endometriosis”. Arch. Gynecol. Obstet., 2012, 285, 479.

[8] Kobayashi H.: “Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis”. Int. J. Clin. Oncol., 2009, 14, 378.

[9] Buck Louis G.M., Hediger M.L., Peterson C.M., Croughan M., Sundaram R., Stanford J., et al.: “Incidence of endometriosis by study population and diagnostic method: The endo study”. Fertil. Steril., 2011, 96, 360.

[10] Dotlic J., Terzic M., Likic I., Atanackovic J., Ladjevic N.: “Evaluation of adnexal masses: correlation of clinical stage, ultrasound and hystopathological findings”. Vojnosanit. Pregl., 2011, 68, 861.

[11] Terzic M., Stimec B.: “Primary endometrioid adenocarcinoma of the fallopian tube”. Z. Onkol., 2000, 32, 114.

[12] Vlahos N.F., Kalampokas T., Fotiou S.:“Endometriosis and ovarian cancer: a review”. Gynecol. Endocrinol., 2010, 26, 213.

[13] Speeckaert M.M., Speeckaert R., Delanghe J.R.: “Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker”. Adv. Clin. Chem., 2013, 59, 1.

[14] Hamed E.O., Ahmed H., Sedeek O.B., Mohammed A.M., Abd-Alla A.A., Abdel Ghaffar H.M.: “Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response”. Diagn. Pathol., 2013, 8, 11.

[15] Terzic M., Dotlic J., Likic I., Ladjevic N., Brndusic N., Arsenovic N., et al.: “Current diagnostic approach to patients with adnexal masses: which tools are relevant in routine praxis?” Chin. J. Cancer. Res., 2013, 25, 55.

[16] Terzic M., Dotlic J., Likic I., Ladjevic N., Brndusic N., Mihailovic T., et al.: “Predictive factors of malignancy in patients with adnexal masses”. Eur. J. Gynaec. Oncol., 2013, 34, 65.

[17] Kajihara H., Yamada Y., Kanayama S., Furukawa N., Noguchi T., Haruta S., et al.: “Clear cell carcinoma of the ovary: Potential pathogenic mechanisms (Review)”. Oncol. Rep., 2010, 23, 1193.

[18] Worley M.J.J., Welch W.R., Berkowitz R.S., Ng S.W.: “Endometriosis-Associated Ovarian Cancer: A Review of Pathogenesis“. Int. J. Mol. Sci., 2013, 14, 5367.

[19] Tanase Y., Yamada Y., Shigetomi H., Kajihara H., Oonogi A., Yoshizawa Y., et al.: “Modulation of estrogenic action in clear cell carcinoma of the ovary (Review)”. Exp. Ther. Med., 2012, 3, 18.

[20] Munksgaard P.S., Blaakaer J.: “The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations“. Gynecol. Oncol., 2012, 124, 164

[21] Gounaris I., Charnock-Jones D.S., Brenton J.D.: “Ovarian clear cell carcinoma—bad endometriosis or bad endometrium?” J. Pathol., 2011, 225, 157.

[22] Xiao W., Awadallah A., Xin W.: “Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma”. Int. J. Clin. Exp. Pathol., 2012, 5, 642.

[23] Choi J.Y., Han H.H., Kim Y.T., Lee J.H., Kim B.G., Kang S., Cho N.H.: “Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression”. Yonsei. Med. J., 2017, 58, 59.

[24] Yamashita Y., Akatsuka S., Shinjo K., Yatabe Y., Kobayashi H., Seko H., et al.: “Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened Prognosis“. PLoS One, 2013, 8, e57724.